ADMA Biologics Inc (ADMA) Director Eric I. Richman Acquires 25,000 Shares of Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Eric I. Richman acquired 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was bought at an average price of $2.15 per share, with a total value of $53,750.00. Following the transaction, the director now directly owns 31,300 shares in the company, valued at $67,295. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

ADMA Biologics Inc (ADMA) opened at $2.48 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics Inc has a 1 year low of $2.01 and a 1 year high of $6.88.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.29). ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%. The company had revenue of $3.40 million during the quarter, compared to the consensus estimate of $3.52 million. sell-side analysts expect that ADMA Biologics Inc will post -2.25 EPS for the current fiscal year.

WARNING: “ADMA Biologics Inc (ADMA) Director Eric I. Richman Acquires 25,000 Shares of Stock” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.truebluetribune.com/2017/11/14/adma-biologics-inc-adma-director-eric-i-richman-acquires-25000-shares-of-stock.html.

Separately, ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply